Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

AbbVie and Anima Biotech collaborate on mRNA biology modulators

The biotech could receive up to $540m in milestone payments for three targets

- PMLiVE

AbbVie and Immunome agree on multi-year oncology collaboration

The companies will identify up to ten antibody-target pairs using Immunome's discovery engine

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

Biogen Idec building

Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab

Genentech will have sole decision-making rights on glofitamab's commercialisation in the US

- PMLiVE

AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients

In Scotland, there are around 44,000 people living with the progressive autoimmune disease

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

AbbVie’s Rinvoq granted NICE recommendation as ulcerative colitis treatment

The recommendation is for adults living with the condition in England and Wales

- PMLiVE

AbbVie’s Skyrizi receives EC approval for active Crohn’s disease

The approval makes Skyrizi the first specific IL-23 inhibitor as a Crohn's treatment in the EU

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

AbbVie to acquire DJS Antibodies in $255m cash deal

The agreement includes DJS-002, an experimental drug for idiopathic pulmonary fibrosis

- PMLiVE

Biogen doses first patient with litifilimab in cutaneous lupus erythematosus study

The phase 2/3 study is expected to be conducted at approximately 238 sites worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links